Fluvastatin helps interferon-based therapy in chronic hepatitis C: Fact or fiction?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 1, 2013, Pages 7-9

  Hsu, Ching Sheng ^a,d   Kao, Jia Horng ^b,c  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d TZU CHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANTIVIRUS AGENT; ERYTHROPOIETIN; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 28B; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADD ON THERAPY; ANEMIA; BLOOD TRANSFUSION; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; EDITORIAL; ENZYME ACTIVITY; FATTY LIVER; GENOTYPE; HEALTH CARE QUALITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; LIPID METABOLISM; LIPOGENESIS; LIVER FAILURE; LIVER FIBROSIS; LIVER HISTOLOGY; LOW DRUG DOSE; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RELAPSE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; VIRUS LOAD; VIRUS REPLICATION;

EID: 84871654269     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12024     Document Type: Editorial

References (20)

1. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-244.
2. Hsu CS, Kao JH. Hepatitis C infection and metabolic syndrome. J. Formos. Med. Assoc. 2010; 109: 403-407.
3. Huang H, Sun F, Owen DM etal. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc. Natl. Acad. Sci. U.S.A. 2007; 104: 5848-5853.
4. Miyanari Y, Atsuzawa K, Usuda N etal. The lipid droplet is an important organelle for hepatitis C virus production. Nat. Cell Biol. 2007; 9: 1089-1097.
5. Waris G, Felmlee DJ, Negro F, Siddiqui A. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J. Virol. 2007; 81: 8122-8130.
6. Wu C, Gilroy R, Taylor R etal. Alteration of hepatic nuclear receptor-mediated signaling pathways in hepatitis C virus patients with and without a history of alcohol drinking. Hepatology 2011; 54: 1966-1974.
7. Hsu CS, Liu CJ, Liu CH etal. Metabolic profiles in patients with chronic hepatitis C: a case-control study. Hepatol. Int. 2008; 2: 250-257.
8. Perlemuter G, Sabile A, Letteron P etal. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002; 16: 185-194.
9. Hsu CS, Liu CH, Liu CJ etal. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. Am. J. Gastroenterol. 2009; 104: 598-604.
10. Harrison SA, Rossaro L, Hu KQ etal. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010; 52: 864-874.
11. Kondo C, Atsukawa M, Tsubota A etal. An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin. J. Viral Hepat. 2012; 19: 615-622.
12. Atsukawa M, Tsubota A, Kondo C etal. Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b. J. Gastroenterol. Hepatol. 2013; 28: 51-56.
13. Hsu CS, Kao JH. Boceprevir for chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 365: 176-177; author reply 7-8.
14. Thomas DL, Thio CL, Martin MP etal. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
15. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
16. Bain VG, Lee SS, Peltekian K etal. Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin. Aliment. Pharmacol. Ther. 2008; 28: 43-50.
17. Shiffman ML, Salvatore J, Hubbard S etal. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007; 46: 371-379.
18. Myers RP, Patel K, Pianko S, Poynard T, McHutchison JG. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. J. Viral Hepat. 2003; 10: 16-22.
19. Chen CL, Yang HI, Yang WS etal. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135: 111-121.
20. Gane EJ, Roberts SK, Stedman CA etal. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 1467-1475.